Medicine and Dentistry
Pediatrics
100%
Malignant Neoplasm
55%
Neoplasm
40%
Oncology
33%
Immunoglobulin
33%
Acute Myeloid Leukemia
33%
Pediatric Hematology
33%
Plasma Exchange
33%
Crizotinib
33%
5 (2,6 Dichlorobenzylsulfonyl) 3 [3,5 Dimethyl 4 [2 (1 Pyrrolidinylmethyl) 1 Pyrrolidinylcarbonyl] 1h Pyrrol 2 Ylmethylene] 1,3 Dihydro 2h Indol 2 One
33%
Sorafenib
33%
Gene Rearrangement
33%
Atypical Hemolytic Uremic Syndrome
33%
Childhood Cancer
33%
Spindle Cell Carcinoma
33%
Infusion
33%
Pediatric Cancer
33%
Treatment Effect
33%
Cancer Treatment
33%
Dose Response
33%
Disease
33%
Analgesia
27%
Cytotoxic Chemotherapy
22%
Spindle Cell
22%
Late Effect
17%
Dinutuximab
16%
End Stage Renal Disease
16%
Hepatocyte Growth Factor
15%
Drug Megadose
13%
Thyroid Cancer
13%
Salivary Gland
13%
Neuroblastoma Cell Line
12%
Monoclonal Antibody
11%
Catecholamine Metabolism
11%
Epileptic Absence
11%
Side Effect
11%
Gene Fusion
11%
Immunotherapy
11%
Immunomodulating Agent
11%
Tyrosine-Kinase Inhibitor
11%
Bereavement
8%
Medicine
8%
Long Term Survival
6%
Second Cancer
6%
Breast Cancer
6%
Meningioma
6%
Sarcoma
6%
Thyroid Gland
6%
Health Outcomes
6%
Radiation Response
6%
Keyphrases
Professionalism Education
33%
Pediatric
33%
Children with Cancer
33%
Naxitamab
33%
Pain Mitigation
33%
Excess Relative Risk
33%
Cancer Treatment
33%
PHA665752
33%
Sorafenib
33%
Relapsed or Refractory
33%
Sorafenib Treatment
33%
Acute Myeloid Leukemia
33%
Cytotoxic Chemotherapy
22%
Very Late Recurrence
16%
PLEKHH2
16%
Atypical HUS
16%
Acute Risk
16%
Complement Pathway
16%
Pediatric Cancer Survivors
11%
Pediatric Cancer
11%
Conditional Poisson Regression
11%
Subsequent Primary Cancer
11%
Childhood Cancer Patients
11%
Breast Gland
11%
Radiation Dose-response Relationship
11%
Treatment Side Effects
11%
Targeted Immunotherapy
11%
Long-term Adverse Effects
11%
Therapy Intensification
11%
Molecular Targeted Agents
11%
Immunotherapeutics
11%
Late Effects
11%
Targeted Agents
11%
Foundation Funding
8%
Carbon Metabolism Pathway
8%
Neuroblastoma Cell Line
7%
Novel Curriculum
5%
Formal Curriculum
5%
Reflective Communication
5%
Pediatric Patients
5%
Coping with Death
5%
Risk Stratification
5%
Poor Prognosis
5%
Cure Rate
5%
Sustained Remission
5%
Acute Lymphoblastic Leukemia
5%
Leukemogenesis
5%
Overall Survival Rate
5%
Kinase Inhibitor
5%
Lag behind
5%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
75%
Sorafenib
66%
Childhood Cancer
66%
Acute Myeloid Leukemia
66%
Dinutuximab
33%
5 (2,6 Dichlorobenzylsulfonyl) 3 [3,5 Dimethyl 4 [2 (1 Pyrrolidinylmethyl) 1 Pyrrolidinylcarbonyl] 1h Pyrrol 2 Ylmethylene] 1,3 Dihydro 2h Indol 2 One
33%
Basal Cell Carcinoma
33%
Monoclonal Antibody
22%
Chemotherapy
19%
Disease
17%
Hepatocyte Growth Factor
13%
Cytotoxic Chemotherapy
13%
Thyroid Cancer
13%
Dose-Response Relationship
13%
Ketamine
11%
Gabapentin
11%
Neuroblastoma
11%
Pain
11%
Narcotic Analgesic Agent
11%
Remission
8%
Meningioma
6%
Sarcoma
6%
Long Term Survival
6%
Second Cancer
6%
Side Effect
6%
Neoplasm
6%
Breast Cancer
6%
Immunotherapy
6%
Primary Tumor
6%
Host Factor
6%
Immunomodulating Agent
6%
Non Melanoma Skin Cancer
6%
Ionizing Radiation
6%
Minimal Residual Disease
6%
Survival Rate
5%
Salicylate Sodium
5%
Acute Lymphoblastic Leukemia
5%
Leukemogenesis
5%
Protein Kinase Fer
5%
Phosphotransferase Inhibitor
5%
Overall Survival
5%